Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 6/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3219452 | 0.94 | GPR52 (0.59) | GPR52MRGPRX4S1PR5S1PR4SPHK2 | |
| SCHEMBL1851537 | 0.89 | GPR52 (0.53) | GPR52MRGPRX4S1PR5S1PR4NPC1 | |
| SCHEMBL1848618 | 0.88 | GPR52 (0.77) | GPR52MRGPRX4S1PR5S1PR4 | |
| SCHEMBL1850409 | 0.86 | GPR52 (0.54) | GPR52MRGPRX4S1PR5S1PR4CYP2C9 | |
| SCHEMBL1851733 | 0.85 | GPR52 (0.76) | GPR52MRGPRX4S1PR5S1PR4KDM1A | |
| SCHEMBL3219750 | 0.82 | GPR52 (0.74) | GPR52MRGPRX4S1PR5S1PR4SPHK2 | |
| SCHEMBL3208645 | 0.82 | GPR52 (0.53) | GPR52S1PR5S1PR4NPC1CYP1A2 | |
| SCHEMBL1875707 | 0.79 | GPR52 (0.50) | GPR52S1PR5S1PR4NPC1CYP1A2 | |
| SCHEMBL1854619 | 0.79 | GPR52 (0.68) | GPR52S1PR5S1PR4HPGDS | |
| SCHEMBL1858531 | 0.79 | GPR52 (0.62) | GPR52MRGPRX4S1PR5S1PR4SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885MRGPRX4 287/4885S1PR5 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.